Argenica Therapeutics (ASX: $AGN) announces positive results from pilot study on ARG-007 efficacy

Argenica Therapeutics Limited (ASX: $AGN) has announced the successful results from a pilot study evaluating the efficacy of ARG-007 in a ferret preclinical model of mild to moderate traumatic brain injury (modTBI). The study demonstrated significant reduction in damage to brain cells and inflammation markers, indicating the potential of ARG-007 as a therapeutic drug following TBI.

Dr Liz Dallimore, Managing Director of Argenica, comments on the study results

Dr Liz Dallimore, Managing Director of Argenica, expressed, 'The data generated from this new model of TBI is greatly encouraging because it supports and affirms the positive findings in our previous studies in rodents, showing ARG-007 has significant potential as a therapeutic drug following TBI. We look forward to continuing to work with the University of Adelaide to expand this program of work to ensure we have robust preclinical data to build a strong scientific and clinical rationale to progress ARG-007 into a Phase 2 clinical trial in TBI patients.'

Summary of ARG-007 study results and future plans

The pilot study demonstrated that ARG-007 significantly reduced damage to brain cells and inflammation markers in a ferret model of modTBI, indicating its potential as a therapeutic drug for TBI. Argenica plans to advance the preclinical efficacy studies in TBI, including validating the study in a larger ferret study. The company aims to build a strong scientific and clinical rationale to progress ARG-007 into a Phase 2 clinical trial in TBI patients, based on the robust preclinical data set on the efficacy of ARG-007 in TBI.